Just who is at risk? the ethics of environmental regulation

Human and Experimental Toxicology

Volumn 30, Issue 8, 2011, Pages 795-819

  Simon, Ted ^a  

^a Ted Simon LLC   (United States)

Author keywords

human toxicology; pollution environmental toxicology; regulatory toxicology; risk assessment; risk communication

Indexed keywords

ACETYLSALICYLIC ACID; BENZENE; CORTICOSTEROID; IBUPROFEN; TRICLOSAN;

ARTICLE; BIRTH CONTROL; CANCER RISK; CARDIOVASCULAR RISK; DRUG INDUSTRY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HAZARD; ENVIRONMENTAL HEALTH; ETHICAL THEORY; FOOD INDUSTRY; GENETIC SUSCEPTIBILITY; HEAD INJURY; HEART INFARCTION; HEREDITY; HUMAN; HYGIENE PRODUCT; INTRACRANIAL PRESSURE; LIFESTYLE; MONTE CARLO METHOD; PEDIATRIC INTENSIVE CARE NURSING; PERSONAL HYGIENE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT;

DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INDUSTRY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; ETHICAL THEORY; FOOD INDUSTRY; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; HUMANS; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES;

EID: 79960828003     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110379252     Document Type: Article

References (193)

1. Cherry J., Fraedrich J. Perceived risk, moral philosophy and marketing ethics: mediating influences on sales managers' ethical decision-making. J Bus Res 2002 ; 55: 951-962.
2. Aven T. On the ethical justification for the use of risk acceptance criteria. Risk Anal 2007 ; 27: 303-312. (Pubitemid 46776184)
3. Fennell D., Plummer R., and Marschke M. Is adaptive co-management ethical? J Environ Manage 2008 ; 88: 62-75. (Pubitemid 351618091)
4. Kant I. Groundwork of the Metaphysics of Morals. 1785; Radford, VA: A & D Publishing, 2008.
5. Hobbes T. Leviathan. 1651. Cambridge, UK: Cambridge University Press, 1991, 1996.
6. Locke J. Two Treatises of Government. 1689. New Haven, CT: Yale University Press, 2003.
7. Rousseau JJ On the social contract. In Gourevitch V (ed.) The social contract and other later political writings. 1762. New York: Cambridge University Press, 1997.
8. Bentham J. The Principles of Morals and Legislation. 1789. Amherst, NY: Prometheus Books, 1988.
9. Mill JS On Liberty. 1859; In The Basic writings of John Stuart mill: on liberty, the subjection of women and utilitarianism. Introduction by Schneewind JB. New York: Random House, 2002.
10. Mill JS Utilitarianism 1863; In The Basic Writings of John Stuart Mill: On Liberty, the Subjection of Women and Utilitarianism. Introduction by Schneewind JB. New York: Random House, 2002.
11. Tal A. Assessing the environmental movement's attitudes toward risk assessment. Environ Sci Technol 1997 ; 31: 470A - 476A. (Pubitemid 27426096)
12. Simon T. In defense of risk assessment: a reply to the environmental justice movement's critique. Hum Ecol Risk Assess 2000 ; 6: 555-560.
13. Kriebel D., Tickner J., Epstein P., Lemons J., Levins R., Loechler EL, et al. The precautionary principle in environmental science. Environ Health Perspect 2001 ; 109: 871-876. (Pubitemid 32976250)
14. Wilson K., Leonard B., Wright R., Graham I., Moffet J., Pluscauskas M., et al. Application of the precautionary principle by senior policy officials: results of a Canadian survey. Risk Anal 2006 ; 26: 981-988. (Pubitemid 44341860)
15. van Asselt MB, Vos E. The precautionary principle in times of intermingled uncertainty and risk: some regulatory complexities. Water Sci Technol 2005 ; 52: 35-41. (Pubitemid 41700885)
16. Mayer B., Brown P., and Linder M. Moving further upstream: from toxics reduction to the precautionary principle. Public Health Rep 2002 ; 117: 574-586. (Pubitemid 36222519)
17. Ricci PF, Cox LA Jr, and MacDonald TR Precautionary principles: a jurisdiction-free framework for decision-making under risk. Hum Exp Toxicol 2004 ; 23: 579-600. (Pubitemid 40096862)
18. Gee D., Krayer von Krauss MP Late lessons from early warnings: towards precaution and realism in research and policy. Water Sci Technol 2005 ; 52: 25-34. (Pubitemid 41700884)
19. Krayer von Krauss M., van Asselt MB, Henze M., Ravetz J., and Beck MB Uncertainty and precaution in environmental management. Water Sci Technol 2005 ; 52: 1-9. (Pubitemid 41700881)
20. Kiker GA, Bridges TS, Varghese A., Seager PT, and Linkov I. Application of multicriteria decision analysis in environmental decision making. Integr Environ Assess Manag 2005 ; 1: 95-108.
21. Linkov I., Satterstrom FK, Kiker G., Batchelor C., Bridges T., and Ferguson E. From comparative risk assessment to multi-criteria decision analysis and adaptive management: recent developments and applications. Environ Int 2006 ; 32: 1072-1093. (Pubitemid 44637296)
22. Linkov I., Satterstrom FK, Kiker G., Seager TP, Bridges T., and Gardner KH Multicriteria decision analysis: a comprehensive decision approach for management of contaminated sediments. Risk Anal 2006 ; 26: 61-78.
23. Linkov I., Satterstrom FK, Kiker GA, Bridges TS, Benjamin SL, and Belluck DA From optimization to adaptation: shifting paradigms in environmental management and their application to remedial decisions. Integr Environ Assess Manag 2006 ; 2: 92-98.
24. Seager TP, Satterstrom FK, Linkov I., Tuler SP, and Kay R. Typological review of environmental performance metrics (with illustrative examples for oil spill response). Integr Environ Assess Manag 2007 ; 3: 310-321.
25. Lester RR, Green LC, and Linkov I. Site-specific applications of probabilistic health risk assessment: review of the literature since 2000. Risk Anal 2007 ; 27: 635-658.
26. Yatsalo BI, Kiker GA, Kim SJ, Bridges TS, Seager TP, Gardner K., et al. Application of multicriteria decision analysis tools to two contaminated sediment case studies. Integr Environ Assess Manag 2007 ; 3: 223-33.
27. Suedel BC, Kim J., Clarke DG, and Linkov I. A risk-informed decision framework for setting environmental windows for dredging projects. Sci Total Environ 2008 ; 403: 1-11.
28. Dakins ME, Toll JE, Small MJ, and Brand KP Risk-based environmental remediation: Bayesian Monte Carlo analysis and the expected value of sample information. Risk Anal 1996 ; 16: 67-79.
29. Briggs AH Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 ; 17: 479-500. (Pubitemid 30398806)
30. Briggs AH, O'Brien BJ, and Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002 ; 23: 377-401. (Pubitemid 34508080)
31. O'Brien BJ, Briggs AH Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002 ; 11: 455-468. (Pubitemid 36096865)
32. Office of Management and Budget (OMB) Circular A-4: Regulatory Analysis, 17 September, 2003.
33. Ricci PF, Cox LA Jr, and MacDonald TR Science-policy in environmental and health risk assessment: if we cannot do without, can we do better? Hum Exp Toxicol 2006 ; 25: 29-43. (Pubitemid 43163886)
34. Sauerland S., Maegele M. A CRASH landing in severe head injury. Lancet 2004 ; 364: 1291-1292. (Pubitemid 39335807)
35. Edwards P., Arango M., Balica L., Cottingham R., El- Sayed H., Farrell B., et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005 ; 365: 1957-1959.
36. Marsh PD Microbiological aspects of the chemical control of plaque and gingivitis. J Dent Res 1992 ; 71: 1431-1438.
37. Rao SP, Surolia A., and Surolia N. Triclosan: a shot in the arm for antimalarial chemotherapy. Mol Cell Biochem 2003 ; 253: 55-63. (Pubitemid 37321712)
38. Jones RD, Jampani HB, Newman JL, and Lee AS Triclosan: a review of effectiveness and safety in health care settings. Am J Infect Control 2000 ; 28: 184-196. (Pubitemid 30226494)
39. Zorrilla LM, Gibson EK, Jeffay SC, Crofton KM, Setzer WR, Cooper RL, et al. The effects of triclosan on puberty and thyroid hormones in male Wistar rats. Toxicol Sci 2009 ; 107: 56-64.
40. Calafat AM, Ye X., Wong LY, Reidy JA, and Needham LL Urinary concentrations of triclosan in the US population: 2003-2004. Environ Health Perspect 2008 ; 116: 303-307. (Pubitemid 351395596)
41. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 ; 343: 1520-1528.
42. Silverstein FE, Faich G., Goldstein JL, Simon LS, Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 ; 284: 1247-1255.
43. Ray WA, Stein CM, Daugherty JR, Hall K., Arbogast PG, and Griffin MR COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002 ; 360: 1071-1073.
44. Waksman JC, Brody A., and Phillips SD Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe? Ann Pharmacother 2007 ; 41: 1163-1173. (Pubitemid 47122553)
45. National Academy of Sciences (NAS). Risk assessment in the federal government: managing the process. Washington, DC: National Academy Press, 1983.
46. National Academy of Sciences (NAS). Science and judgment in risk assessment. Washington, DC: National Academy Press, 1994.
47. Federal Commission on Risk Assessment and Risk Management. Framework for environmental health risk management. Washington, DC. 1997.
48. Boffetta P., Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003 ; 68: 71-94. (Pubitemid 38258221)
49. Boffetta P. Human cancer from environmental pollutants: the epidemiological evidence. Mutat Res 2006 ; 608: 157-162. (Pubitemid 44311607)
50. Boffetta P., McLaughlin JK, la Vecchia C., Autier P., and Boyle P. 'Environment' in cancer causation and etiological fraction: limitations and ambiguities. Carcinogenesis 2007 ; 28: 913-915. (Pubitemid 47072172)
51. Saracci R., Vineis P. Disease proportions attributable to environment. Environ Health 2007 ; 6: 38.
52. US Environmental Protection Agency (USEPA) Guidelines for Carcinogen Risk Assessment, http://www.epa.gov/ncea, 2005.
53. Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 2004 ; 91: 1983-1989.
54. Crump KS, Hoel DG, Langley CH, and Peto R. Fundamental carcinogenic processes and their implications for low dose risk assessment. Cancer Res 1976 ; 36: 2973-2979.
55. Crump KS An improved procedure for low-dose carcinogenic risk assessment from animal data. J Environ Pathol Toxicol Oncol 1984 ; 5: 339-348. (Pubitemid 15162433)
56. Crump KS, Guess HA, and Deal KL Confidence intervals and test of hypotheses concerning dose response relations inferred from animal carcinogenicity data. Biometrics 1977 ; 33: 437-451. (Pubitemid 8194073)
57. National Research Council (NRC) Science and Decisions: Advancing Risk Assessment. Committee on Improving Risk Analysis Approaches 2008; at http://www.nap.edu/catalog/12209.html ( 2008, accessed January 18).
58. Lovell DP Dose-response and threshold-mediated mechanisms in mutagenesis: statistical models and study design. Mutat Res 2000 ; 464: 87-95. (Pubitemid 30035293)
59. Kirsch-Volders M., Aardema M., and Elhajouji A. Concepts of threshold in mutagenesis and carcinogenesis. Mutat Res 2000 ; 464: 3-11. (Pubitemid 30035285)
60. Moustacchi E. DNA damage and repair: consequences on dose-responses. Mutat Res 2000 ; 464: 35-40. (Pubitemid 30035288)
61. Muller L., Kasper P. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat Res 2000 ; 464: 19-34. (Pubitemid 30035287)
62. Amdur MO, Doull J., and Klaassen CD Casarett and Doull's Toxicology: The basic science of poisons. 4 th ed. New York: McGraw-Hill Inc, 1993.
63. Forslund J., Samakovlis E., Johansson MV, and Barregard L. Does remediation save lives? - On the cost of cleaning up arsenic-contaminated sites in Sweden. Sci Total Environ 2010 ; 408: 3085-3091.
64. Barnes DG, Dourson M. Reference dose (RfD): description and use in health risk assessments. Regul Toxicol Pharmacol 1988 ; 8: 471-486. (Pubitemid 19014888)
65. Dourson M. Uncertainty factors in noncancer risk assessment. Regul Toxicol Pharmacol 1996 ; 24: 107. (Pubitemid 26400644)
66. Dourson ML, Stara JF Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol 1983 ; 3: 224-238. (Pubitemid 14229334)
67. Ritter L., Totman C., Krishnan K., Carrier R., Vézina A., and Morisset V. Deriving uncertainty factors for threshold chemical contaminants in drinking water. J Toxicol Environ Health B Crit Rev 2007 ; 10: 527-557. (Pubitemid 47575087)
68. Renwick AG Safety factors and establishment of acceptable daily intakes. Food Addit Contam 1991 ; 8: 135-149.
69. Price PS, Keenan RE, Swartout JC, Gillis CA, Carlson-Lynch H., and Dourson ML An approach for modeling noncancer dose responses with an emphasis on uncertainty. Risk Anal 1997 ; 17: 427-437. (Pubitemid 27423962)
70. Swartout JC, Price PS, Dourson ML, Carlson-Lynch HL, and Keenan RE A probabilistic framework for the reference dose (probabilistic RfD). Risk Anal 1998 ; 18: 271-282.
71. Vermeire T., Stevenson H., Peiters MN, Rennen M., Slob W., and Hakkert BC Assessment factors for human health risk assessment: a discussion paper. Crit Rev Toxicol 1999 ; 29: 439-490. (Pubitemid 29477890)
72. Hattis D. Pharmacogenetics: ethnic differences in reactions to drugs and xenobiotics. Science 1986 ; 234: 222-223.
73. Hattis D. Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Toxicology 1996 ; 111: 5-14. (Pubitemid 26247030)
74. Hattis D., Erdreich L., and Ballew M. Human variability in susceptibility to toxic chemicals-a preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal 1987 ; 7: 415-426. (Pubitemid 18033523)
75. Hattis D., Ginsberg G., Sonawane B., Smolenski S., Russ A., Kozlak M., et al. Differences in pharmacokinetics between children and adults-II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 2003 ; 23: 117-142. (Pubitemid 36255427)
76. Renwick AG, Lazarus NR Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 1998 ; 27: 3-20. (Pubitemid 28289017)
77. IPCS (International Programme on Chemical Safety) Chemical-Specific Adjustment Factors For Interspecies Differences And Human Variability: Guidance Document For Use Of Data In Dose/Concentration-Response Assessment. 2005.
78. Dorne JL, Renwick AG The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol Sci 2005 ; 86: 20-26. (Pubitemid 41511345)
79. White RH, Cote I., Zeise L., Fox M., Dominici F., Burke TA, et al. State-of-the-science workshop report: issues and approaches in low-dose-response extrapolation for environmental health risk assessment. Environ Health Perspect 2009 ; 117: 283-287.
80. Calabrese EJ The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch Toxicol 2009 ; 83: 203-225.
81. Rhomberg LR Linear low-dose extrapolation for noncancer responses is not generally appropriate. Environ Health Perspect 2009 ; 117: A141 - A142 ; author reply A2 - A3.
82. Burke TA, Dominici F., Fox M., White RH, Cote I., Hattis DB, et al. Linear low dose extrapolation for non-cancer responses: Burke et al. Respond. Environ Health Perspect 2009 ; 117: A142.
83. Deal FH, Richardson FC, and Swenberg JA Dose response of hepatocyte replication in rats following continuous exposure to diethylnitrosamine. Cancer Res 1989 ; 49: 6985-6988. (Pubitemid 20016580)
84. Fukushima S., Wanibuchi H., Morimura K., Wei M., Nakae D., Konishi Y., et al. Lack of a dose-response relationship for carcinogenicity in the rat liver with low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline or N-nitrosodiethylamine. Jpn J Cancer Res 2002 ; 93: 1076-1082. (Pubitemid 35314951)
85. Waddell WJ, Fukushima S., and Williams GM Concordance of thresholds for carcinogenicity of N-nitrosodiethylamine. Arch Toxicol 2006 ; 80: 305-309. (Pubitemid 43725213)
86. Williams GM, Iatropoulos MJ, Jeffrey AM, Luo FQ, Wang CX, and Pittman B. Diethylnitrosamine exposure-responses for DNA ethylation, hepatocellular proliferation, and initiation of carcinogenesis in rat liver display non-linearities and thresholds. Arch Toxicol 1999 ; 73: 394-440.
87. Williams GM, Iatropoulos MJ, Wang CX, Ali N., Rivenson A., Peterson LA, et al. Diethylnitrosamine exposure-responses for DNA damage, centrilobular cytotoxicity, cell proliferation and carcinogenesis in rat liver exhibit some non-linearities. Carcinogenesis 1996 ; 17: 2253-2258. (Pubitemid 26372067)
88. Tsuda H., Fukushima S., Wanibuchi H., Morimura K., Nakae D., Imaida K., et al. Value of GST-P positive pre-neoplastic hepatic foci in dose-response studies of hepatocarcinogenesis: evidence for practical thresholds with both genotoxic and nongenotoxic carcinogens. A review of recent work. Toxicol Pathol 2003 ; 31: 80-86. (Pubitemid 36169424)
89. Zhang Q., Pi J., Woods CG, and Andersen ME Phase I to II cross-induction of xenobiotic metabolizing enzymes: a feedforward control mechanism for potential hormetic responses. Toxicol Appl Pharmacol 2009 ; 237: 345-356.
90. Zhang Q., Pi J., Woods CG, and Andersen ME A systems biology perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol 2010 ; 244: 84-97.
91. Mayr E. The growth of biological thought: diversity, evolution and inheritance. Cambridge, MA: Harvard University Press, 1982.
92. Nilsson R. Control of chemicals in Sweden: an example of misuse of the ''precautionary principle''. Ecotoxicol Environ Saf 2004 ; 57: 107-117. (Pubitemid 38175214)
93. US Environmental Protection Agency (USEPA) Risk Assessment Guidance for Superfund (RAGS): Vol I. Human Health Evaluation Manual (HHEM) (Part A, Baseline Risk Assessment). Interim Final. Office of Emergency and Remedial Response, Washington, DC. EPA/540/1-89/002. NTIS PB90-155581, 1989.
94. US Environmental Protection Agency (USEPA) Final Guidelines for Exposure Assessment. EPA/600/Z-92/ 001. 57 Federal Register, 22888-22938, 29 May 1992.
95. Burmaster DE, Lehr JH It's Time to Make Risk Assessment a Science. Ground Water Monit Rev 1991 ; XI: 5-15, Summer.
96. Burmaster DE, von Stackelberg K. Using Monte Carlo simulations in public health risk assessments: estimating and presenting full distributions of risk. J Exposure Anal Environ Epidemiol 1991 ; 1: 491-512.
97. Burmaster DE, Harris RH The magnitude of compounding conservatisms in superfund risk assessments. Risk Anal 1993 ; 13: 131-134.
98. Burmaster DE, Anderson PD Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments. Risk Anal 1994 ; 14: 477-481.
99. Thompson KM, Burmaster DE, and Crouch EA Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal 1992 ; 12: 53-63.
100. von Stackelberg K., Burmaster DE Compounding conservatisms - EPA's health risk assessment methods. HazMat World 1993 ; 6: 46-47.
101. US Environmental Protection Agency (USEPA) 'Guidance on Risk Characterization for Risk Managers and Risk Assessors', Memorandum from F Henry Habicht II. 1992, http://www.epa.gov/oswer/riskassessment/pdf/habicht.pdf
102. Cullen AC Measures of compounding conservatism in probabilistic risk assessment. Risk Anal 1994 ; 14: 389-393. (Pubitemid 24300005)
103. Nieuwenhuijsen M., Paustenbach D., and Duarte-Davidson R. New developments in exposure assessment: the impact on the practice of health risk assessment and epidemiological studies. Environ Int 2006 ; 32: 996-1009. (Pubitemid 44637297)
104. van der Voet H., Slob W. Integration of probabilistic exposure assessment and probabilistic hazard characterization. Risk Anal 2007 ; 27: 351-371. (Pubitemid 46776188)
105. Gaylor DW, Kodell RL Percentiles of the product of uncertainty factors for establishing probabilistic reference doses. Risk Anal 2000 ; 20: 245-250. (Pubitemid 30354443)
106. Bartsch H., Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996 ; 104: 569-577. (Pubitemid 26196406)
107. Bonafe M., Barbi C., Storci G., Salvioli S., Capri M., Olivieri F., et al. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Exp Gerontol 2002 ; 37: 1263-1271. (Pubitemid 35418285)
108. Bouchardy C., Benhamou S., Jourenkova N., Dayer P., and Hirvonen A. Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer 2001 ; 32: 109-112. (Pubitemid 32372603)
109. Sultatos LG, Pastino GM, Rosenfeld CA, and Flynn EJ Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans. Toxicol Sci 2004 ; 78: 20-31. (Pubitemid 38351420)
110. Bounias M. Etiological factors and mechanism involved in relationships between pesticide exposure and cancer. J Environ Biol 2003 ; 24: 1-8. (Pubitemid 36222218)
111. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 2006 ; 162: 16-28. (Pubitemid 43245599)
112. Clapper ML Genetic polymorphism and cancer risk. Curr Oncol Rep 2000 ; 2: 251-256.
113. Clapper ML, Szarka CE Glutathione S-transferases- biomarkers of cancer risk and chemopreventive response. Chem Biol Interact 1998 ; 111-112: 377-388. (Pubitemid 28271956)
114. Coles BF, Anderson KE, Doerge DR, Churchwell MI, Lang NP, and Kadlubar FF Quantitative analysis of interindividual variation of glutathione S-transferase expression in human pancreas and the ambiguity of correlating genotype with phenotype. Cancer Res 2000 ; 60: 573-579. (Pubitemid 30094553)
115. Dandara C., Li DP, Walther G., and Parker MI Gene-environment interaction: the role of SULT1A1 and CYP3A5 polymorphisms as risk modifiers for squamous cell carcinoma of the oesophagus. Carcinogenesis 2006 ; 27: 791-797.
116. Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saude Publica 2002 ; 18: 357-377.
117. Ingelman-Sundberg M. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001 ; 120: 259-268. (Pubitemid 32375092)
118. Jirtle RL, Sander M., and Barrett JC Genomic imprinting and environmental disease susceptibility. Environ Health Perspect 2000 ; 108: 271-278. (Pubitemid 30195587)
119. Lakhani NJ, Venitz J., Figg WD, and Sparreboom A. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Curr Drug Metab 2003 ; 4: 505-513. (Pubitemid 37536871)
120. Linder MW, Valdes R. Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001 ; 25: 405-413. (Pubitemid 32656295)
121. Miller MC 3rd, Mohrenweiser HW, and Bell DA Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001 ; 120: 269-280. (Pubitemid 32375093)
122. Sun J., Turner A., Xu J., Grönberg H., and Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007 ; 25: 250-259. (Pubitemid 46670748)
123. Woodward ER, Maher ER Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer 2006 ; 13: 415-425. (Pubitemid 43886666)
124. Yan H., Zhou W. Allelic variations in gene expression. Curr Opin Oncol 2004 ; 16: 39-43. (Pubitemid 38703470)
125. Pool-Zobel B., Veeriah S., and Bohmer FD Modulation of xenobiotic metabolising enzymes by anticarcinogens - focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutat Res 2005 ; 591: 74-92. (Pubitemid 41656060)
126. Ulrich CM, Curtin K., Potter JD, Bigler J., Caan B., and Slattery ML Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005 ; 14: 2509-2516. (Pubitemid 41752708)
127. Steinmaus C., Yuan Y., Kalman D., Atallah R., and Smith AH Intraindividual variability in arsenic methylation in a US population. Cancer Epidemiol Biomarkers Prev 2005 ; 14: 919-924. (Pubitemid 40478557)
128. Barlow S., Renwick AG, Kleiner J., Bridges JW, Busk L., Dybing E., et al. Risk assessment of substances that are both genotoxic and carcinogenic report of an International Conference organized by EFSA and WHO with support of ILSI Europe. Food Chem Toxicol 2006 ; 44: 1636-1650.
129. Holsapple MP, Pitot HC, Cohen SM, Boobis AR, Klaunig JE, Pastoor T., et al. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 2006 ; 89: 51-56. (Pubitemid 43013754)
130. Meek ME, Bucher JR, Cohen SM, Dellarco V., Hill RN, Lehman-McKeeman LD, et al. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 2003 ; 33: 591-653. (Pubitemid 38040084)
131. Seed J., Carney EW, Corley RA, Crofton KM, DeSesso JM, Foster PM, et al. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol 2005 ; 35: 664-672.
132. Simon T., Kirman CR, Aylward LL, Budinsky RA, Rowlands JC, Long TF, et al. Estimates of cancer potency of 2,3,4,7,8-pentachlorodibenzofuran using both nonlinear and linear approaches. Toxicol Sci 2008 ; 106: 519-537.
133. Simon T., Aylward LL, Kirman CR, Rowlands JC, and Budinsky RA Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics. Toxicol Sci 2009 ; 112: 490-506.
134. Simon T., Manning R. Development of a reference dose for the persistent congeners of weathered toxaphene based on in vivo and in vitro effects related to tumor promotion. Regul Toxicol Pharmacol 2006 ; 44: 268-281.
135. Albert RE, Altshuler B. Assessment of environmental carcinogen risks in terms of life shortening. Environ Health Perspect 1976 ; 13: 91-94.
136. Yanysheva NY, Antomonov YG, Albert RE, Altshuler B., and Friedman L. Approaches to the formulation of standards for carcinogenic substances in the environment. Environ Health Perspect 1979 ; 30: 81-85. (Pubitemid 9236569)
137. Conolly RB, Gaylor DW, and Lutz WK Population variability in biological adaptive responses to DNA damage and the shapes of carcinogen dose-response curves. Toxicol Appl Pharmacol 2005 ; 207: 570-575.
138. Lutz WK Dose-response relationships in chemical carcinogenesis reflect differences in individual susceptibility. Consequences for cancer risk assessment, extrapolation, and prevention. Hum Exp Toxicol 1999 ; 18: 707-712.
139. Lutz WK Susceptibility differences in chemical carcinogenesis linearize the dose-response relationship: threshold doses can be defined only for individuals. Mutat Res 2001 ; 482: 71-76. (Pubitemid 32787083)
140. Lutz WK A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Hum Exp Toxicol 2000 ; 19: 566-568 ; discussion 71-72. (Pubitemid 32117867)
141. Lutz WK Differences in individual susceptibility to toxic effects of chemicals determine the dose-response relationship and consequences of setting exposure standards. Toxicol Lett 2002 ; 126: 155-158. (Pubitemid 34113974)
142. Lutz WK, Lutz RW, and Andersen ME Dose-incidence relationships derived from superposition of distributions of individual susceptibility on mechanism-based dose responses for biological effects. Toxicol Sci 2006 ; 90: 33-38. (Pubitemid 43264724)
143. Lutz WK, Fekete T. Endogenous and exogenous factors in carcinogenesis: limits to cancer prevention. Int Arch Occup Environ Health 1996 ; 68: 120-125. (Pubitemid 26040930)
144. Lutz WK, Gaylor DW Dose-response relationships for cancer incidence reflect susceptibility distributions. Chem Res Toxicol 2008 ; 21: 971-972 ; author reply 2-3.
145. Bruckner JV Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report. Regul Toxicol Pharmacol 2000 ; 31: 280-285. (Pubitemid 30640372)
146. Dorne JL, Walton K., and Renwick AG Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem Toxicol 2001 ; 39: 1153-1173. (Pubitemid 33030228)
147. Bosma PJ, Chowdhury JR, Bakker C., Gantla S., de Boer A., Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995 ; 333: 1171-1175.
148. Sampietro M., Iolascon A. Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes. Haematologica 1999 ; 84: 150-157. (Pubitemid 29479662)
149. Strassburg CP Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008 ; 9: 703-715.
150. Strassburg CP, Lankisch TO, Manns MP, and Ehmer U. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol 2008 ; 82: 415-433.
151. Whelan EM The US government versus carcinogens. CA Cancer J Clin 1978 ; 28: 239-240.
152. Quarles JR Existing legislation and government regulatory agencies. Bull NY Acad Med 1978 ; 54: 442-443.
153. Moon YJ, Wang X., and Morris ME Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006 ; 20: 187-210. (Pubitemid 43087702)
154. Wogan GN, Hecht SS, Felton JS, Conney AH, and Loeb LA Environmental and chemical carcinogenesis. Semin Cancer Biol 2004 ; 14: 473-486. (Pubitemid 39360995)
155. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Reducing Environmental Cancer Risk: What We Can Do Now, 2010.
156. American Cancer Society. Cancer and the Environment. ACS Pressroom Blog 2010 at http://acspressroom.wordpress.com/2010/05/06/cancer-and-the-environment/
157. Campbell TC, Campbell TM The China study: startling implications for diet, weight loss, and long-term health. Dallas, TX: Benbella Press, 2006.
158. Shamasunder B., Bero L. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA 2002 ; 288: 738-744. (Pubitemid 34848227)
159. Forman MR Changes in dietary fat and fiber and serum hormone concentrations: nutritional strategies for breast cancer prevention over the life course. J Nutr 2007 ; 37: 170S - 174S. (Pubitemid 46052877)
160. Massart F., Saggese G. Oestrogenic mycotoxin exposures and precocious pubertal development. Int J Androl 2010 ; 33: 369-376.
161. Daxenberger A., Ibarreta D., and Meyer HH Possible health impact of animal oestrogens in food. Hum Reprod Update 2001 ; 7: 340-355. (Pubitemid 32440296)
162. Reeves J. $700 Million deal announced in Anniston PCB Cases. Associated Press, August 20, 2003.
163. Reeves JA PCB plaintiffs angry with settlement. Associated Press, 23 March 2004.
164. Silverstone AE, Bartell S., and Pavuk M. The Anniston/ Calhoun PCB consortium health study: origins and objectives. Presented at the National Institutes of Environmental Health Science 5th PCB Workshop, University of Iowa, 2008.
165. Silverstone AE, et al. PCB Levels, Diabetes and Cardiovascular Disease in the Anniston Community Health Survey Population. Presented at the National Institutes of Environmental Health Science 5th PCB Workshop, University of Iowa, May, 2008.
166. Anniston Star. Medical Study finds PCB Problems in East Alabama City, 2 April 2008.
167. Silverstone AE Comments made at the 2009 USEPA dioxin workshop. Cincinnati, OH, 18-20 February 2009.
168. Foushee HR Anniston community health survey: self-reported conditions and perceptions of exposure. Presented at the National Institutes of Environmental Health Science 5th PCB Workshop, University of Iowa, May, 2008.
169. Kimbrough RD, Krouskas CA Human exposure to polychlorinated biphenyls and health effects: a critical synopsis. Toxicol Rev. 2003 ; 22: 217-233. (Pubitemid 38997052)
170. Matsumura F. On the significance of the role of cellular stress response reactions in the toxic actions of dioxin. Biochem Pharmacol 2003 ; 66: 527-540. (Pubitemid 37281272)
171. Remillard RB, Bunce NJ Linking dioxins to diabetes: epidemiology and biologic plausibility. Environ Health Perspect 2002 ; 110: 853-858.
172. Johansson S., Iliadou A., Bergvall N., dé Fairé U., Kramer MS, Pawitan Y., et al. The association between low birth weight and type 2 diabetes: contribution of genetic factors. Epidemiology 2008 ; 19: 659-665.
173. Ness RB, Zhang J., Bass D., and Klebanoff MA Interactions between smoking and weight in pregnancies complicated by preeclampsia and small-for- gestational-age birth. Am J Epidemiol 2008 ; 168: 427-433.
174. Porta M. Persistent organic pollutants and the burden of diabetes. Lancet 2006 ; 368: 558-589.
175. Rignell-Hydbom A., Rylander L., and Hagmar L. Exposure to persistent organochlorine pollutants and type 2 diabetes mellitus. Hum Exp Toxicol 2007 ; 26: 447-452. (Pubitemid 47057004)
176. Wang SL, Tsai PC, Yang CY, and Leon Guo Y. Increased risk of diabetes and polychlorinated biphenyls and dioxins: a 24-year follow-up study of the Yucheng cohort. Diabetes Care 2008 ; 31: 1574-1579.
177. Advisory Committee on Population Health (ACPH) Toward a Healthy Future - A Second Report on the Health of Canadians 1999, http://www.phac-aspc.gc.ca/ph- sp/report-rapport/toward/report-eng.php
178. Henry CJ Evolution of toxicology for risk assessment. Int J Toxicol 2003 ; 22: 3-7. (Pubitemid 36362989)
179. US Environmental Protection Agency (USEPA) Interim Policy on Genomics. Science Policy Council 2007 ; at http://www.epa.gov/OSA/spc/genomics.htm
180. US Environmental Protection Agency (USEPA) National Oil and Hazardous Substances Pollution Contingency Plan. (NCP) Proposed Rule. 53 Federal Register 51394 (December 21, 1988 ).
181. US Environmental Protection Agency (USEPA) Risk Assessment Guidance for Superfund Volume 3 Part A: Process for Conducting Probabilistic Risk Assessment (RAGS 3A), Office of Solid Waste and Emergency Response. EPA 540-R-02-002, OSWER 9285.7-45 2001 ; at http://www.epa.gov/swerrims/riskassessment/rags3adt/index. htm
182. US Environmental Protection Agency (USEPA) Memorandum from Margaret Stasikowski, Health Effects Division to Health Effects Division Staff. HED SOP 97.2 Interim Guidance for Conducting Aggregate Exposure and Risk Assessments (11/26/97) November 26, 1997. Office of Pesticide Programs, Office of Prevention, Pesticides, and Toxic Substances, Washington, DC.
183. U.S. Environmental Protection Agency (USEPA) Issue Paper for the March 1997 Scientific Advisory Panel (SAP) Meeting. Aggregate Exposure Assessment as Required by the Food Quality Protection Act (FQPA) of 1996-Interim Approach. Office of Pesticide Programs, Office of Prevention, Pesticides, and Toxic Substances, Washington, D.C. 1997 ; Available: http://www.epa.gov/scipoly/sap/ 1997/index.htm
184. U.S. Environmental Protection Agency (USEPA) General Principles for Performing Aggregate Exposure and Risk Assessments, Office of Pesticide Programs, November 28, 2001 at http://www.epa.gov/oppfead1/trac/science/
185. Health Canada. Federal Contaminated Site Risk Assessment In Canada. Part V: Guidance On Complex Site Specific Human Health Risk Assessment Of Chemicals (SSRACHEM). 6-28-2007.
186. REACH Technical Guidance Document on Risk Assessment in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances, Commission Regulation (EC) No. 1488/ 94 on Risk Assessment for Existing Substances, Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market. Part I. European Chemicals Bureau 2008.
187. Sunstein CR Laws of fear: beyond the precautionary principle. Cambridge University Press, 2005.
188. US Environmental Protection Agency (USEPA). Regional Screening Level Tables 2009 at http://www.epa.gov/reg3hwmd/risk/human/rb-concentration-table/ index.htm
189. U.S. Environmental Protection Agency (USEPA) IRIS file on Benzene. 2003 ; at http://www.epa.gov/ncea/iris/subst/0276.htm
190. Crump KS Risk of benzene-induced leukemia: a sensitivity analysis of Pliofilm cohort with additional follow-up and new exposure estimates. J Toxicol Environ Health 1994 ; 42: 219-242. (Pubitemid 24197312)
191. Rothman N., Li GL, Dosemeci M., Bechtold WE, Marti GE, Wang YZ, et al. Hematotoxicity among Chinese workers heavily exposed to benzene. Am J Ind Med 1996 ; 29: 236-246. (Pubitemid 26080773)
192. US Environmental Protection Agency (USEPA) Toxicological Review of Benzene (NonCancer Effects) EPA/635/R-02/001F. 2002.
193. US Environmental Protection Agency (USEPA) Memorandum from Carole Browner on Risk Characterization. Office of the Administrator. Washington, DC, 1995.